API

Glucosamine (750mg) + Diacerein (50mg) + Methyl Sulfonyl Methane (250mg)

Drug classification

Musculoskeletal agent; specific subclass: symptomatic slow-acting drugs for osteoarthritis (SYSADOA).

Dosage form

Film-coated oral tablet containing glucosamine, diacerein, and methyl sulfonyl methane.

API strength per dosage

Dose

Lubry-GM Tablet is typically taken as one tablet twice daily with meals in adults. Safety and efficacy in children have not been established. Use with caution in patients with renal or hepatic impairment; dose adjustment or avoidance may be necessary, especially due to diacerein. Always follow prescribing information and consult a healthcare professional.

Mechanism of action

Glucosamine supports cartilage matrix synthesis by stimulating glycosaminoglycan production. Diacerein inhibits interleukin-1β activity, reducing cartilage degradation and inflammation. Methyl sulfonyl methane (MSM) may exert anti-inflammatory effects by modulating oxidative stress. Together, these agents aim to reduce joint inflammation and pain, and slow osteoarthritis progression.

Indications

Osteoarthritis

Side effects

Nausea Diarrhea Constipation Indigestion Heartburn Urine discoloration

Pregnancy category

Safety of glucosamine, diacerein, and methyl sulfonyl methane in pregnancy is not established; use only if potential benefits justify potential risks.

Precautions

Assess for shellfish allergy, monitor liver function, caution in hepatic or renal impairment, monitor for gastrointestinal symptoms (diarrhea, abdominal pain), avoid in pregnancy and lactation unless prescribed, monitor for hypersensitivity reactions, assess for drug interactions, use with caution in elderly, monitor symptom improvement and adverse effects regularly.

Contraindications

Hypersensitivity to glucosamine, diacerein, methyl sulfonyl methane, or excipients, severe hepatic impairment, severe renal impairment, pregnancy, breastfeeding, children, history of or active bowel obstruction or inflammatory bowel disease.